BEVERLY JCG LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.024 SGD | -.--% |
|
-14.29% | -52.00% |
| Sales 2022 | 10.51M 7.84M | Sales 2023 | 8.04M 6M | Capitalization | 29.11M 21.71M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -1.49M | Net income 2023 | -2M -1.49M | EV / Sales 2022 | 2.17 x |
| Net Debt 2022 | 3.11M 2.32M | Net Debt 2023 | 2.26M 1.68M | EV / Sales 2023 | 3.9 x |
| P/E ratio 2022 |
-9.2
x | P/E ratio 2023 |
-10.1
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.67% |
More Fundamentals
* Assessed data
More news
Beverly JCG Ltd. is a Singapore-based company, which is engaged in the investment holding and provision of management services. The Company operates through three segments: aesthetic medical and healthcare, trading and distribution, and investment and others. The aesthetic medical and healthcare segment is engaged in the provision of aesthetic medical services, including the provision of aesthetic medical, beauty and wellness services. The trading and distribution segment is engaged in trading and distribution of steel raw materials, instruments and semi-finished products for steel mills, iron and steel foundries and aluminum smelters in the Asia-Pacific region and provision of ancillary services. The investment and others segment is engaged in the business of investment holding, provision of management services and provision of marketing, distribution and related services. Its subsidiaries include Albedo Corporation Pte. Ltd. and Beverly Wilshire Medical Centre (JB) Sdn. Bhd.
Calendar
2024-08-14
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +19.84% | 84.94B | |
| -25.24% | 74.07B | |
| -1.20% | 26.15B | |
| +4.56% | 18.03B | |
| -9.29% | 17.38B | |
| +4.52% | 16.01B | |
| +78.16% | 13.7B | |
| +77.84% | 13.13B | |
| -26.14% | 12.74B |
- Stock Market
- Equities
- 9QX Stock
- 9QX Stock
